Latest News & Features
Big Pharma
As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates. 21 March 2023
Big Pharma
Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030. 21 March 2023
Biotechnology
New R&D tax incentive announced for SMEs in UK Budget | Funding for medicines regulator aims to open up drug approvals | ‘Hidden benefits’ in Budget for industry | Reaction from Bioindustry Association, Potter Clarkson, Mischon de Reya, Marks & Clerk, Taylor Wessing. 16 March 2023
Medtech
Dispute relates to AstraZeneca ‘Breztri’ brand | Court says no likelihood of confusion with earlier marks | Full details of reasoning. 16 March 2023
Americas
Medtech company wins reversal of earlier ruling | Door opens to mount a challenge of controversial rule | USPTO director‘s updated guidelines influence court’s reasoning. 14 March 2023
Biotechnology
“Customer suit exception” is rejected by district judge | Suit between Chr. Hansen and Glycosyn is ongoing. 14 March 2023
Biotechnology
The Pharmaceutical Accountability Foundation has accused the pharma giant of excessively pricing its blockbuster drug, and believes it could influence the regulation of pricing and patent policy for global medicines in the process. 9 March 2023
Big Pharma
Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand. 9 March 2023
Big Pharma
The University of Minnesota had raised three key issues on appeal | Sovereign immunity was at the heart of the years-long dispute. 7 March 2023
Big Pharma
The Roche subsidiary says the licensee owes payments on “stockpile” of MS drug Tysabri. 7 March 2023